These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 17076654)
1. Disease modifying therapy for AD? Golde TE J Neurochem; 2006 Nov; 99(3):689-707. PubMed ID: 17076654 [TBL] [Abstract][Full Text] [Related]
2. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]
3. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Song MS; Rauw G; Baker GB; Kar S Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381 [TBL] [Abstract][Full Text] [Related]
4. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Kayed R; Jackson GR Curr Opin Immunol; 2009 Jun; 21(3):359-63. PubMed ID: 19482462 [TBL] [Abstract][Full Text] [Related]
5. Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed. Hutton M; McGowan E Neuron; 2004 Aug; 43(3):293-4. PubMed ID: 15294135 [TBL] [Abstract][Full Text] [Related]
6. Current and future therapy in Alzheimer's disease. van Marum RJ Fundam Clin Pharmacol; 2008 Jun; 22(3):265-74. PubMed ID: 18485144 [TBL] [Abstract][Full Text] [Related]
7. [Recent progress in the development of disease-modifying therapies for Alzheimer's disease]. Abe K Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Feb; 30(1):1-8. PubMed ID: 20297736 [TBL] [Abstract][Full Text] [Related]
8. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Oddo S; Billings L; Kesslak JP; Cribbs DH; LaFerla FM Neuron; 2004 Aug; 43(3):321-32. PubMed ID: 15294141 [TBL] [Abstract][Full Text] [Related]
9. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies. Cummings JL Rev Neurol Dis; 2007; 4(2):57-62. PubMed ID: 17609636 [TBL] [Abstract][Full Text] [Related]
12. [From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease]. Franke AG; Lieb K; Fellgiebel A Fortschr Neurol Psychiatr; 2009 Jun; 77(6):326-33. PubMed ID: 19504422 [TBL] [Abstract][Full Text] [Related]
13. Drugs targeting Alzheimer's disease: some things old and some things new. Michaelis ML J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663 [TBL] [Abstract][Full Text] [Related]